CorrlensCorrlens
Correlate

Correlation Analysis

Alnylam Pharmaceuticals, Inc. vs VISA Inc.

ALNY vs V

+0.745

Strong positive

When one moves up, the other tends to follow.

ALNY logo

Alnylam Pharmaceuticals, Inc.

ALNY

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Market cap 43.8B · 2,500 employees

V

VISA Inc.

V

Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.

Market cap 583.4B

Apr 9, 2021 — Apr 7, 2026Daily1,253 data pointsStockStockFinancials

Time Series

Relative Performance

Green: ALNYGray: V36 of 1,253 points (sampled)

Who Moves First

V leads ALNY by 6 days

V tends to move before ALNY.

After testing 13 timing shifts, the strongest relationship was +0.748 (they moved in the same direction).

Do They Crash Together?

Correlation by Market Regime

How these series behave when markets are rising, falling, or diverging. A correlation that holds in drawdowns is very different from one that only works in rallies.

Both Rising

+0.767

10 periods · Return correlation when both series rose

Both Falling

+0.455

8 periods · Return correlation when both series fell

Diverging

-0.593

17 periods · Return correlation when series moved apart

R-Squared

55.5%

Share of variance in one series explained by the other.

Trend Agreement

56.8%

How often both series moved in the same direction period-to-period.

Overlap Quality

1,253

Deep shared window — 1,253 usable pairs.

Significance

p < 0.001

95% CI: [0.720, 0.769]

Scatter

XY Regression

98100200300400497192.8200250300350372.1Alnylam Pharmaceuticals, Inc.VISA Inc.Data pointsFit (r = 0.745)

Pipeline

Data quality details

Pipeline Summary

1,253 paired data points survived the daily window.

Raw input

1,253

1,254

Normalized

1,253

1,254

Prepared

1,253

1,254

Aligned

1,253

1,253

Invalid removed

0

A: 0 / B: 0

Duplicates removed

0

A: 0 / B: 0

Alignment drops

1

A: 0 / B: 1

Series A

ALNY logo

Alnylam Pharmaceuticals, Inc.

ALNY

Market cap 43.8B · 2,500 employees

Stock · 1,253 raw → 1,253 prepared

Series B

V

VISA Inc.

V

Market cap 583.4B

Stock · 1,254 raw → 1,254 prepared

Sign agreement

100.0%

How often both values share the same sign.

Zero crossings

41

Estimated crossover points between normalized spreads.

Slope

0.4494

Linear regression slope.

Intercept

160.3135

Linear regression intercept.

Related Extremes

Highest and Lowest Correlated

Saved 6 hours ago · ID: stock-alny-vs-stock-v-daily